Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo Dainippon Shoots for Sales of 600 Billion Yen in FY2022, Revving Up “Post-Latuda” Pipeline Acquisition
Sumitomo Dainippon Pharma unveiled its new five-year business plan on April 11, setting out a sales target of 600 billion yen in FY2022 through March 2023, some 140 billion yen higher than the 466.8 billion yen reported in FY2017, while…
To read the full story
Related Article
BUSINESS
- GSK Files Hep B Drug in Japan as First Global Submission
February 27, 2026
- Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
- Sawai to End Teribone Generic Sales following Patent Settlement
February 26, 2026
- Darzquro Seen as Emerging Standard in High-Risk SMM: Specialist
February 26, 2026
- Towa Wins Pediatric Autism Use for Abilify Generic
February 26, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…